BBBY, QRTEA and VIRX are among pre market gainers
franckreporter/iStock via Getty Images
- CinCor Pharma (CINC) +138% as AstraZeneca set to acquire it in up to $1.8B deal.
- Amryt Pharma (AMYT) +108% Chiesi Farmaceutici S.p.A. to acquire Amryt Pharma.
- Albireo Pharman (ALBO) +93% as Ipsen set to acquire it for $952M.
- Sonnet BioTherapeutics Holdings (SONN) +27% announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer.
- Duck Creek Technologies (DCT) +46% to be Acquired by Vista Equity Partners for $2.6 Billion.
- Voyager Therapeutics (VYGR) +36% enter strategic collaboration for development and commercialization of Voyager’s GBA1 Program and other next-generation Gene Therapies for Neurological Diseases.
- CureVac (CVAC) +23% as analysts cheer mRNA based COVID and flu shots.
- Kronos Bio (KRON) +25% announces discovery collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology.
- Paya Holdings (PAYA) +25% stock climbs after Nuvei agrees to acquire Paya for $1.3B cash.
- Day One Biopharmaceuticals (DAWN) +24% stock surges 20% as brain tumor drug shows promise in mid-stage study.
- GreenLight Biosciences (GRNA) +23% and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines.
- Bed Bath & Beyond (BBBY) +21%.
- Ocugen (OCGN) +20% as U.S.-based trial for COVID vaccine meets main goals.
- IO Biotech (IOBT) +18% Provides Business Update.
- Exact Sciences (EXAS) +17% Q4 earnings call release.
- Viracta Therapeutics (VIRX) +15%.
- Clearmind Medicine (CMND) +11%.
- Pacific Biosciences of California (PACB) +10% announces record orders, including orders for 76 Revio Systems received in the Fourth Quarter of 2022.
- Qurate Retail (QRTEA) +3%.
- Arhaus (ARHS) +9% Provides Fourth Quarter and Full Year 2022 Revenue Outlook Update.
- Jianzhi Education Technology Group Company (JZ) +8%.
- LexinFintech Holdings (LX) +8%.
- Indonesia Energy Corporation (INDO) +8%.
- Phathom Pharmaceuticals (PHAT) +2% announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease.
- Cyclo Therapeutics (CYTH) +8% announces first patient dosed in Phase 2b Study of Trappsol Cyclo for the Treatment of Early Alzheimer’s Disease.